Immuno-oncologySunrock Biopharma reports new CCR9-targeting ADCsSunrock Biopharma SL has disclosed antibody-drug conjugates (ADCs) comprising an antibody targeting C-C chemokine receptor type 9 (CCR9) linked to camptothecin derivatives through a linker found to be potentially useful for the treatment of cancer.